Abstract
Background: Although known as a rare adverse drug reaction (ADR), drug fever (DF) remains an important issue in medicine, with the risk of leading to inappropriate and potentially harmful diagnostic and therapeutic interventions. Only sparse data regarding DF have been published.
Objective: The aim of the study was to investigate which drugs were associated with DF, and report outcomes.
Methods: Cases of DF without skin reactions were selected from all ADRs reported from 1986 to 2007 in the French National Pharmacovigilance Database. Drugs potentially responsible for DF were assessed using a qualitative case-by-case analysis (Naranjo’s criteria) and quantitative measurement (proportional reporting ratio [PRR]). A drug was implicated as the cause of DF when the following criteria were validated: three or more cases and PRR of at least two with a Chi-squared value of at least four.
Results: A total of 167 DF cases involving 115 drugs were eligible. Based on the PRR, 22 drugs were significantly associated with DF. Antibacterials represented the most frequently reported drugs, including amikacin (PRR 39.6 [95% CI 23.6, 69.0], oxacillin (9.1 [3.6, 23.4]), cefotaxime (5.5 [2.0, 15.3]), ceftriaxone (5.4 [2.6, 11.3]), rifampicin (4.0 [1.8, 9.2]), vancomycin (4.0 [1.4, 11.5]), ciprofloxacin (3.1 [1.2, 8.0]), isoniazid (3.9 [1.4, 11.4]), pristinamycin (3.1 [1.0, 9.1]) and cotrimoxazole (2.6 [1.2, 5.8]). Median time [interquartile range] from drug administration to fever onset was 2 days [1.0–10.5]. A diagnosis of DF was made following cessation of the suspected drugs (3 days [1.0–11.5] after fever onset. Drug rechallenge was performed (38.0%), resulting in recurrence of DF in all cases. DF resulted in life-threatening events (0.6%), hospitalization or prolonged hospital stay (24.5%) and persistent disability (0.6%). Final outcome was favourable in 96.9% of cases after drug discontinuation.
Conclusion: Diagnosing DF is challenging. Based on this large series, antibacterials remain the major class of drugs responsible for DF.
Similar content being viewed by others
References
Mackowiak PA, Le Maistre CF. Drug fever: a critical appraisal of conventional concepts. An analysis of 51 epi sodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 1987; 106: 728–33
Johnson DH, Cunha BA. Drug fever. Infect Dis Clin North Am 1996 Mar; 10: 85–91
Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301–6
Kumar KL, Reuler JB. Drug fever. West J Med 1986; 144: 753–5
Lipsky BA, Hirschmann JV. Drug fever. JAMA 1981; 245: 851–4
Young EJ, Fainstein V, Musher DM. Drug-induced fever: cases seen in the evaluation of unexplained fever in a general hospital population. Rev Infect Dis 1982; 4: 69–77
Tabor PA. Drug-induced fever. Drug Intell Clin Pharm 1986; 20: 413–20
Patel RA, Gallagher JC. Drug fever. Pharmacotherapy 2010; 30: 57–69
Oizumi K, Onuma K, Watanabe A, et al. Clinical study of drug fever induced by parenteral administration of antibiotics. Tohoku J Exp Med 1989; 159: 45–56
Tisdale J, Miller D. Drug induced disease: prevention, detection, management. Bethesda (MD): American Society of Health System Pharmacists, 2010
Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10:483–6
Thiessard F, Roux E, Miremont-Salamé G, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986–2001). Drug Saf 2005; 28: 731–40
Bégaud B, Martin K, Haramburu F, et al. Rates of spontaneous reporting of adverse drug reactions in France [letter]. JAMA 2002; 288: 1588
Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994; 106: 1124–8
Wood K, On behalf of the MedDRA Working Party. The medical dictionary for drug regulatory affairs (MedDRA). Pharmacoepidemiol Drug Saf 1994; 3: 7–13
World Health Organization Collaborating Center for Drug Statistics Methodology. ATC/DDD index 2012 [online]. Available from URL: http://www.whocc.no/atc_ddd_index/ [Accessed 2012 Jun 26]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45
World Health Organization. International classification of diseases and related health problems 10th revision, 2007 [online]. Available from URL: http://www.who.int/classifications/icd/en/ [Accessed 2012 Jun 26]
CIOMS. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Saf 1992; 1:39–45
Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf 2005; 28: 981–1007
Evans SJ. Pharmacovigilance: a science or fielding emergencies? Stat Med 2000; 19: 3199–209
Barbado FJ, Gómez-Cerezo J, Peña JM, et al. Fever of unknown origin: classic and associated with human immunodeficiency virus infection. a comparative study. J Med 2001; 32: 152–62
Barbado FJ, Vazquez JJ, Pena JM, et al. Fever of unknown origin: a survey on 133 patients. J Med 1984; 15: 185–92
Colpan A, Onguru P, Erbay A, et al. Fever of unknown origin: analysis of 71 consecutive cases. Am J Med Sci 2007; 334: 92–6
de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO): I. A prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medi cine (Baltimore) 1997; 76: 392–400
Erten N, Saka B, Ozturk G, et al. Fever of unknown origin: a report of 57 cases. Int J Clin Pract 2005; 59: 958–60
Kazanjian PH. Fever of unknown origin: review of 86 patients treated in community hospitals. Clin Infect Dis 1992; 15: 968–73
Knockaert DC, Vanneste LJ, Vanneste SB, et al. Fever of unknown origin in the 1980s: an update of the diagnostic spectrum. Arch Intern Med 1992 Jan; 152: 51–5
Knockaert DC, Vanderschueren S, Blockmans D. Fever of unknown origin in adults: 40 years on. J Intern Med 2003 Mar; 253: 263–75
Larson EB, Featherstone HJ, Petersdorf RG. Fever of un determined origin: diagnosis and follow-up of 105 cases, 1970–1980. Medicine (Baltimore) 1982; 61: 269–92
Liu K-S, Sheng W-H, Chen Y-C, et al. Fever of unknown origin: a retrospective study of 78 adult patients in Taiwan. J Microbiol Immunol Infect 2003; 36: 243–7
Petersdorf RG, Beeson PB. Fever of unexplained origin:report on 100 cases. Medicine (Baltimore) 1961; 40: 1–30
Saltoglu N, Tasova Y, Midikli D, et al. Fever of unknown origin in Turkey: evaluation of 87 cases during a nine-year-period of study. J Infect 2004; 48: 81–5
Tabak F, Mert A, Celik AD, et al. Fever of unknown origin in Turkey. Infection 2003; 31: 417–20
Zenone T. Fever of unknown origin in adults: evaluation of 144 cases in a non-university hospital. Scand J Infect Dis 2006; 38: 632–8
Roush MK, Nelson KM. Understanding drug-induced febrile reactions. Am Pharm 1993; NS33(10): 39–42
Harris LF, Holdsambeck HK. Drug fever: surprisingly common and costly. Ala Med 1986; 56: 19–22
Grépinet C, Guillocheau E, Berteloot A, et al. Drug-induced fever during treatment with levofloxacin: a case-report [in French]. Therapie 2008; 63: 341–3
Sprague JE, Banks ML, Cook VJ, et al. Hypothalamicpituitary-thyroid axis and sympathetic nervous system in volvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy). J Pharmacol Exp Ther 2003; 305: 159–66
Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998; 83: 2597–607
Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity: a review. Med Toxicol Adverse Drug Exp 1988; 3: 376–86
Darko W, Medicis JJ, Smith A, et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003; 23: 643–50
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385–96
Mannesse CK, van Puijenbroek EP, Jansen PAF, et al. Hyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBase. Drug Saf 2010; 33: 569–78
Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010; 33: 303–14
Strandell J, Bate A, Hägg S, et al. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol 2009; 68: 427–34
Acknowledgements
No sources of funding were used to conduct this study or prepare this manuscript. None of the authors has any conflict of interest.
The authors would like to acknowledge Jenny Lu, MD, from Toxikon Consortium, Chicago, IL, USA, for her review of this manuscript and François Maignen, from the European Medicines Agency, London, UK, for his methodological help. We appreciate the assistance of the French pharmacovigilance centers in our work.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vodovar, D., LeBeller, C., Mégarbane, B. et al. Drug Fever. Drug Saf 35, 759–767 (2012). https://doi.org/10.1007/BF03261972
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03261972